Matrixyl Results Timeline: What Studies Measured, and When

What this page covers, and what it cannot

"Matrixyl" is a trade name used in cosmetic ingredient labelling for palmitoyl pentapeptide-4 (pal-KTTKS), while related trade names such as Matrixyl 3000 refer to blends containing palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7. Questions about a results timeline usually assume that somewhere there is a controlled trial with weekly measurements and a curve showing when a change first became detectable. For the papers verified for this page, that trial does not exist. None of the three verified references is a randomised controlled trial of Matrixyl alone, and none publishes a week-by-week outcome curve for that ingredient.

Rather than fill that gap with speculation, this page does three things: it states plainly where human data on the ingredient itself is absent, it describes what each verified paper actually measured and in which species or setting, and it explains why the measurement design of each study limits the timing conclusions that can be drawn from it. This page is for educational purposes only and is not medical advice; consult a licensed physician before acting on anything you read about a compound, a cosmetic ingredient or a study.

The three verified papers at a glance

Paper by paper: what was measured, in whom

A topical skin-care comparison during radiotherapy

The 2004 report in Strahlentherapie und Onkologie compared Thêta-Cream with Bepanthol lotion in breast cancer patients undergoing radiotherapy, framing the question as whether the cream represented a new prophylactic agent in skin care (PMID 15127162). The population in that study was defined by an oncological treatment context, not by cosmetic photoaging, and the endpoint was prophylaxis of radiation-associated skin changes rather than wrinkle depth, fine lines or collagen-related imaging (PMID 15127162). Because the verified record describes a comparison of two finished topical products, it cannot be read as an isolated test of any one peptide, and it does not supply a schedule of cosmetic measurements at weeks 4, 8 or 12 (PMID 15127162).

Radiotherapy skin-care studies follow the radiation course, which means their observation windows are organised around treatment fractions and follow-up visits rather than around a cosmetic "time to visible change". That is a different clock from the one implied by a results-timeline question, and the two should not be merged.

An animal photodamage experiment — on a different material

The 2019 study in Biological & Pharmaceutical Bulletin examined the reparative effect of Dendrobium officinale protocorms against photodamage caused by UV irradiation in hairless mice (PMID 31061314). That work did not test Matrixyl, palmitoyl pentapeptide-4 or any palmitoylated peptide; the test material was a plant-derived protocorm preparation, and the subjects were hairless mice rather than human volunteers (PMID 31061314). It is included here only as an illustration of how a preclinical photodamage timeline is constructed — a UV-irradiation phase followed by an intervention phase in an animal model — and not as evidence about the ingredient this page discusses (PMID 31061314).

This distinction matters for anyone reading ingredient marketing. Hairless mouse photodamage models use skin that differs from human facial skin in thickness, turnover and UV response, and the irradiation doses used to induce damage are experimental rather than representative of ordinary sun exposure. Translating a rodent repair timeline into weeks of human cosmetic use is not something the verified record supports.

A single split-face case report with instrumented imaging

The 2026 case report in Cureus described use of a serum together with the Infinite Glow device and reported improvement in signs of facial aging in a split-face design assessed with VISIA analysis (PMID 42500768). Researchers used a split-face approach, meaning one side of the face served as the comparison for the other, and outcomes were captured by standardised facial imaging rather than by unaided observation (PMID 42500768). The study was a case report in a single individual, and it combined a serum with a device, so no effect described in it can be attributed to any one formulation component (PMID 42500768).

A single-subject case report sits near the bottom of the evidence hierarchy for timing questions. With one participant and no randomised control group, there is no way to separate an intervention effect from seasonal skin change, hydration status, imaging variability or regression to the mean. The design does, however, illustrate the instrument most often used in cosmetic timing research.

How results timelines are actually built in skin research

Timing claims in cosmetic literature depend almost entirely on when investigators chose to measure. A study that photographs subjects only at baseline and week 12 cannot report anything about week 4, regardless of what happened. Common design elements include:

• Fixed assessment visits. Baseline, then intervals such as monthly, with identical lighting and camera positioning.
• Instrumented imaging. Systems such as VISIA quantify features from standardised photographs, as used in the split-face case report (PMID 42500768).
• Within-subject controls. Split-face or split-body designs reduce between-person variability, again as in that case report (PMID 42500768).
• Clinician grading scales. Ordinal scores applied by blinded assessors.
• Preclinical surrogate endpoints. In animal photodamage work, tissue-level measures are taken at the end of an irradiation-plus-treatment protocol rather than continuously, as in the hairless mouse experiment on a plant protocorm preparation (PMID 31061314).

None of these elements, on their own, produces a number that can be generalised to "when results appear". They produce a measurement at a chosen timepoint in a chosen population under chosen conditions.

Why the verified set cannot generate a week-by-week curve

Three constraints apply simultaneously. First, species: one of the three papers used hairless mice rather than humans (PMID 31061314). Second, subject matter: that same paper tested Dendrobium officinale protocorms, a plant material unrelated to palmitoylated cosmetic peptides (PMID 31061314). Third, design and attribution: the clinical comparison was conducted in breast cancer patients under radiotherapy with a prophylactic skin-care endpoint (PMID 15127162), while the cosmetic-aging report was a single split-face case combining a serum with a device (PMID 42500768).

Put together, the verified set contains one clinical comparison in an oncology setting, one animal experiment on a different material, and one uncontrolled single-subject report. Nothing in that combination supports a statement of the form "a change was measurable at week X" for Matrixyl specifically.

What a Matrixyl-specific timeline study would need

1. An isolated variable. A vehicle-matched comparison in which only the peptide differs between arms, unlike the serum-plus-device combination in the case report (PMID 42500768).
2. Multiple prospectively defined timepoints. Assessments spaced closely enough to identify when a measured difference first emerged, rather than a single endpoint.
3. Human facial skin as the tissue studied, rather than a rodent photodamage model (PMID 31061314).
4. Blinded assessment and adequate sample size, since a single-subject report cannot distinguish signal from ordinary variation (PMID 42500768).
5. A population defined by the question asked. A prophylactic skin-care trial in patients undergoing radiotherapy answers a different question from a cosmetic photoaging trial (PMID 15127162).

Tolerability and Adverse Events: What Studies Report

The verified set does not contain a safety dataset for Matrixyl. The clinical comparison of a cream against a lotion in breast cancer patients under radiotherapy was framed around prophylactic skin care in irradiated skin, a setting in which skin reactions are expected from the radiation itself (PMID 15127162). The hairless mouse experiment examined repair of UV-induced photodamage with a plant protocorm preparation and is an animal study, so its observations do not describe human tolerability (PMID 31061314). The split-face case report described a single individual using a serum with a device and, as an uncontrolled report of one person, cannot establish the frequency of any adverse event (PMID 42500768). No dose, concentration or exposure duration for Matrixyl is stated anywhere on this page, because the verified papers do not supply one.

How to read timeline claims critically

When a timing claim appears — in a product description, a forum post or a summary article — the useful questions are the same ones applied above. Which paper is it drawn from? Was the subject human or animal? Was the tested material the ingredient in question, or a finished product containing many actives? Was there a control? At which timepoints was anything measured? A claim that survives all five questions is rare; the three papers verified here each fail at least one of them when applied to Matrixyl specifically, whether because the species was murine (PMID 31061314), the population and endpoint were oncological (PMID 15127162), or the design was a single uncontrolled case (PMID 42500768).

Stating that plainly is more informative than an invented schedule. Readers interested in cosmetic peptide chemistry, labelling conventions and regulatory status can pursue those topics separately; this page is limited to what the verified record measured and when.

References

• Thêta-Cream versus Bepanthol lotion in breast cancer patients under radiotherapy. A new prophylactic agent in skin care? (Strahlentherapie und Onkologie, 2004)
• The Reparative Effect of Dendrobium officinale Protocorms against Photodamage Caused by UV-Irradiation in Hairless Mice (Biological & Pharmaceutical Bulletin, 2019)
• Use of a Serum With the Infinite Glow® Device Improves Signs of Facial Aging: A Split-Face Case Report Using VISIA Analysis (Cureus, 2026)